162 related articles for article (PubMed ID: 9081388)
1. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer.
Bokemeyer C; Beyer J; Metzner B; Ruther U; Harstrick A; Weissbach L; Kohrmann U; Verbeek W; Schmoll HJ
Ann Oncol; 1996 Jan; 7(1):31-4. PubMed ID: 9081388
[TBL] [Abstract][Full Text] [Related]
2. Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer.
Bokemeyer C; Schmoll HJ; Natt F; Knoche M; Beyer J; Souchon R
J Cancer Res Clin Oncol; 1994; 120(12):754-7. PubMed ID: 7798304
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer.
Bokemeyer C; Gerl A; Schöffski P; Harstrick A; Niederle N; Beyer J; Casper J; Schmoll HJ; Kanz L
J Clin Oncol; 1999 Feb; 17(2):512-6. PubMed ID: 10080593
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel in salvage therapy for germ cell tumors.
Motzer RJ
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-83-S15-85. PubMed ID: 9346229
[TBL] [Abstract][Full Text] [Related]
5. The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors.
Bokemeyer C; Hartmann JT; Kuczyk MA; Truss MC; Beyer J; Jonas U; Kanz L
World J Urol; 1996; 14(6):354-9. PubMed ID: 8986035
[TBL] [Abstract][Full Text] [Related]
6. Recent strategies for the use of paclitaxel in the treatment of urological malignancies.
Bokemeyer C; Hartmann JT; Kuczyk MA; Truss MC; Kollmannsberger C; Beyer J; Jonas U; Kanz L
World J Urol; 1998; 16(2):155-62. PubMed ID: 12073232
[TBL] [Abstract][Full Text] [Related]
7. Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors.
Bokemeyer C
Oncology; 1998; 55(3):177-88. PubMed ID: 9560052
[TBL] [Abstract][Full Text] [Related]
8. Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP.
de Wit R; Louwerens M; de Mulder PH; Verweij J; Rodenhuis S; Schornagel J
Int J Cancer; 1999 Dec; 83(6):831-3. PubMed ID: 10597204
[TBL] [Abstract][Full Text] [Related]
9. Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German Testicular Cancer Study Group (GTCSG).
Bokemeyer C; Kollmannsberger C; Harstrick A; Beyer J; Gerl A; Casper J; Metzner B; Hartmann JT; Schmoll HJ; Kanz L
Int J Cancer; 1999 Dec; 83(6):848-51. PubMed ID: 10597209
[TBL] [Abstract][Full Text] [Related]
10. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.
Kondagunta GV; Bacik J; Donadio A; Bajorin D; Marion S; Sheinfeld J; Bosl GJ; Motzer RJ
J Clin Oncol; 2005 Sep; 23(27):6549-55. PubMed ID: 16170162
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer.
Kollmannsberger C; Gerl A; Schleucher N; Beyer J; Kuczyk M; Rick O; Casper J; Sosada M; Rie C; Kanz L; Bokemeyer C
Anticancer Drugs; 2000 Aug; 11(7):535-9. PubMed ID: 11036955
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
Hainsworth JD; Greco FA
Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer.
Motzer RJ; Sheinfeld J; Mazumdar M; Bains M; Mariani T; Bacik J; Bajorin D; Bosl GJ
J Clin Oncol; 2000 Jun; 18(12):2413-8. PubMed ID: 10856101
[TBL] [Abstract][Full Text] [Related]
14. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors.
Motzer RJ; Bajorin DF; Schwartz LH; Hutter HS; Bosl GJ; Scher HI; Lyn P; Fischer P
J Clin Oncol; 1994 Nov; 12(11):2277-83. PubMed ID: 7525885
[TBL] [Abstract][Full Text] [Related]
16. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
Kollmannsberger C; Rick O; Derigs HG; Schleucher N; Schöffski P; Beyer J; Schoch R; Sayer HG; Gerl A; Kuczyk M; Spott C; Kanz L; Bokemeyer C
J Clin Oncol; 2002 Apr; 20(8):2031-7. PubMed ID: 11956262
[TBL] [Abstract][Full Text] [Related]
17. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
[TBL] [Abstract][Full Text] [Related]
18. [Salvage chemotherapy with paclitaxel, ifosphamide and nedaplatin for relapsed or refractory germ cell cancer].
Nomoto T; Mizutani Y; Mikami K; Nakamura T; Nakanishi H; Kawauchi A; Miki T
Nihon Hinyokika Gakkai Zasshi; 2006 May; 97(4):630-5. PubMed ID: 16768143
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours.
McNeish IA; Kanfer EJ; Haynes R; Giles C; Harland SJ; Driver D; Rustin GJ; Newlands ES; Seckl MJ
Br J Cancer; 2004 Mar; 90(6):1169-75. PubMed ID: 15026797
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]